Heron Therapeutics (HRTX) EBT Margin (2010 - 2026)
Heron Therapeutics' (HRTX) quarterly EBT Margin came in at 5.43% in Q2 2026, down 102.0% on a YoY basis from 271.33% in Q2 2025, and up 60.55% quarter-over-quarter from 13.76% in Q1 2026.
Powered by 
Analysis
Heron Therapeutics (HRTX) EBT Margin (2010 - 2026) Analysis & Trends
Heron Therapeutics (HRTX) has reported EBT Margin for 12 consecutive years, with 5.43% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, EBT Margin fell 102.0% year-over-year to 5.43%; the trailing twelve-month figure through Jun 2026 stood at 5.9% (down 909.0% YoY), and the FY2025 full-year result was 6.58%, up 313.0% from the prior year.
- EBT Margin advanced to 5.43% in Q2 2026 per HRTX's latest filing, from 13.76% in the prior quarter.
- Across five years, EBT Margin topped out at 18.87% in Q4 2024 and bottomed at 268.26% in Q1 2022.
- Historically, EBT Margin has averaged 58.87% across 5 years, with a median of 15.9% in 2024.
- The sharpest annual moves came in 2022 and 2026: EBT Margin soared 19367 bps in 2022, then plunged 2183 bps in 2026.
- Over 5 years, EBT Margin stood at 62.16% in 2022, then soared by 68 bps to 20.08% in 2023, then surged by 194 bps to 18.87% in 2024, then tumbled by 74 bps to 4.93% in 2025, then tumbled by 210 bps to 5.43% in 2026.
- According to Business Quant data, EBT Margin over the past three periods registered 5.43%, 13.76%, and 4.93% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.34 Bn | 192.35 Bn | 7.24 Bn | 27.53% |
| 2 | Gilead Sciences | 180.06 Bn | 176.88 Bn | 6.22 Bn | -131.41% |
| 3 | Vertex Pharmaceuticals | 131.22 Bn | 123.37 Bn | 2.84 Bn | 41.75% |
| 4 | Regeneron Pharmaceuticals | 81.84 Bn | 73.84 Bn | 3.93 Bn | 35.61% |
| 5 | Argenx Se | 60.28 Bn | 55.09 Bn | 1.37 Bn | 35.78% |
| 6 | Moderna | 54.18 Bn | 49.05 Bn | 52.00 Mn | -528.97% |
| 7 | Alnylam Pharmaceuticals | 33.22 Bn | 29.91 Bn | 992.69 Mn | 13.77% |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | 4.84% |
| 9 | Roivant Sciences | 29.06 Bn | 29.06 Bn | 1.16 Mn | -20,427.46% |
| 10 | Heron Therapeutics | 61.54 Mn | 18.87 Mn | 26.09 Mn | -5.43% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -5.43% |
| Mar 31, 2026 | -13.76% |
| Dec 31, 2025 | 4.93% |
| Sep 30, 2025 | -10.71% |
| Jun 30, 2025 | -4.41% |
| Mar 31, 2025 | 8.08% |
| Dec 31, 2024 | 18.87% |
| Sep 30, 2024 | -13.44% |
| Jun 30, 2024 | -17.90% |
| Mar 31, 2024 | -13.89% |
| Dec 31, 2023 | -20.08% |
| Sep 30, 2023 | -79.29% |
| Jun 30, 2023 | -133.55% |
| Mar 31, 2023 | -111.55% |
| Dec 31, 2022 | -62.16% |
| Sep 30, 2022 | -157.88% |
| Jun 30, 2022 | -179.16% |
| Mar 31, 2022 | -268.26% |
| Dec 31, 2021 | -255.84% |
| Sep 30, 2021 | -222.79% |